Indivior Pharmaceuticals, Inc.

Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and commercializing buprenorphine-based prescription medications for treating opioid use disorder and related substance dependence. Its core products include SUBLOCADE, a once-monthly extended-release buprenorphine injection designed for long-acting treatment, and SUBOXONE Film, a sublingual film combining buprenorphine and naloxone for maintenance therapy. These treatments target patients seeking effective options to manage opioid dependence, addressing a critical public health need. Indivior Pharmaceuticals, Inc. operates in key markets including the United States, Europe, Canada, Australia, and other international regions, with a primary emphasis on the U.S. where demand for such therapies is substantial. The company specializes in the addiction treatment segment, providing innovative formulations that improve patient adherence and outcomes compared to daily dosing alternatives. Founded in 2014 and headquartered in North Chesterfield, Virginia, Indivior Pharmaceuticals, Inc. plays a vital role in the global effort to combat the opioid crisis through targeted pharmacotherapies.